Annals of the New York Academy of Sciences 1993: Vol 698 Index

13 Pages·1993·1.3 MB·English

Subject Index
Abdominal incisions, 251 Brachytherapy, 264
Ablation, ovarian, premenopausal women and. Breast cancer
340 adjuvant therapy of, 339
Activin-A, 79 advanced
Adjuvant Chemoendocrine (ACE) study, 347 clodronate in, 367
Adjuvant Tamoxifen Treatment-Offer More? GSTt gene in, 182
(aTTom), 346 mastectomy not used in treatment of, 264
Adjuvant therapy somatuline and, 362
EBCTCG overview of, 339 angiogenesis in, 71
endocrine aspects of, 313 antineoplastic drug resistance and, 289
endocrine factors in outcome of, 330 c-erb-B2 oncoprotein and, 167
Adr”»MCF-7 ceU line, GSTr gene and, 183 cell kinetics in, 186
1 Adriamycin chromosome 17pl3.3 and, 120
1 MPTC-63 pretreatment and, 161 conservative suigery in, 212
resistance to, 183 critical step in, 1
Aesthetic results, double-lumen prostheses and. early
252 ACE study of, 347
Alendronate, 368 chemohormonal adjuvant therapy of, 318
Alkylating agents, resistance to, 303 endocrine factors in, 330
Alopecia, 375 endocrine adjuvant therapy of, 318
Amenorrhea, drug-induced, 331 endocrine aspects of adjuvant treatment of.
American Radiological Society, 153 313
Aminoglutethimide, 357 frequent mutations in, 21
Amsacrine, drug resistance and, 301 growth fectors and, 85
Angiogenesis high-intensity chemotherapy in, 378
prognostic implications of, 75 histologic type of, 114
regulation of, 78 iron metabolism and, 159
tumor growth and, 64 kinetic concepts and, 48
Antibodies, engineered, 413 large, 265
Antibody directed enzyme pro-drug therapy lonidamine in, 349
(ADEPT), 81 marker expression and differentiation in, 143
Anticoagulant activity, pentoxan f)olysulfate metastatic, 349
doses having, 66 Taxol and G-CSF in, 398
Antiestrogen drugs, 177 Taxol cardiotoxicity in, 403
Antimetabolites, resistance to, 304 neoadjuvant chemotherapy and, 193
I Assay systems, cell kinetics and, 282 NM23-H1 and onset of, 139
Autologous bone marrow transplantation positron emission tomography of glucose me¬
(ABMT) tabolism in, 423
1 dose intensity and, 285 prc^esterone receptor determination and, 150
high-dose chemotherapy and, 379 radioimmunoconjugates and, 406
Autologous tissues, reconstruction using, 246 reconstructive suigery in, 219
Axillary involvement, 262 second-line hormone therapy in, 357
Axillary lymph node status, 170 S-phase fraction and, 193
stimulation of, 418
Biological markers, clinical protocol design and. thermographic prognostic procedure in, 153
271 tumor-associated antigens and, 31
Bisphosphonates, 367 Breast Cancer Detection and Demonstration
Bone marrow support, high-dose chemotherapy Projects (BCDDP), 153
without, 389 Breast conserving strategies (BCS) {see Conser¬
Bone metastases, clodronate in, 367 vation, breast)
437
438 ANNALS NEW YORK ACADEMY OF SCIENCES
Breast lobe, 212 premenopausal women and, 340
Breast reconstruction (BR) (see Reconstruction, sequentii, 56
breast) TLI values and, 190
Breast tumor cell invasion, role of CSF-alpha tumor shrinkage and, 48
in, 132 Chromosomal abnormalities, 93
5-Bromo-2-deoxyuridine, DNA content versus Chromosome 17P13.3, 120
incorporation of, 175 Chromosome 17q, definition ofa deletion map
Buthionine sulfoximine (BSO), drug resistance on, 136
and, 302 ctr-platinum-transferrin complex (MPTC-63),
160
C-erb-B2 gene Clearance curves, 205
lL-8 responsiveness and, 127 Clinical protocols, biological markers for de¬
overexpression of, 36 signing, 271
c-er&-B2 oncogene, progesterone receptor and, Clodronate, 367
183 Clonogenicity, 96
c-erb-B2 oncoprotein, receptor status and pro¬ Collagen-induced morphogenesis, 36
liferating activity and, 167 Colony-stimulating factors, severe hematologic
c-erb-El protooncogene, 103 toxicity reversed by, 286
c-Ha-mr gene, loss of heterozygosity of, 10 Combination chemotherapy, 49
c-Ha-«M protooncogene, 103 COMMA D cell line, 24
c-myc oncogene, 94 Conservation, breast
Ci8 reversed-phase HPLC, 206 evolution of treatment towards, 193
Calcium, mechanism of immortalization and, 6 long-term results of, 259
cAMP-dependent protein kinase, 102 strategies, 227
Cancer and Leukemia Group B (CALBG), 51 surgery and therapy for, 260
dose intensity and, 284 surgery in, 212
Carboplatin, 384 Cost benefit analysis, 315
Cardiotoxicity, Taxol, 403 Cyclophosphamide
Cathepsin, prognostic potential of, 273 high-dose, 384
Cathepsin-D, characterization of, 89 lonidamine plus epirubicin and, 350
CD31 (anti-PECAM, platelet/endothelial cell resistance to, 303
adhesion molecule), 72 Cyclophosphamide, epidoxorubicin, 5-fluoro-
Cell kill, dose and, 279 uracil (CEF)
Cell kinetics
DES and, 419
assay systems and, 282
GM-CSF and, 393
clinical relevance of, 186
Cyclophosphamide, methotrexate, 5-fluorouracil
method to study, 175
(CMF), 50
prognostic information provided by, 272
dose intensity of, 285
Cell phenotype, antigen expression and, 32
Cytoreduction, 54
Cell proliferation, growth rate of breast primary
Cytotoxic agents, drug resistance and, 291
cultures and, 2
Cytotoxicity, drug, free radical-mediated, 301
Cell proliferation kinetics
*^®lUdR incorporation based on, 205
radioiodinated lUdR and, 207 Diethilstibestrol (DES), 418
Chemical carcinogens, molecular changes in¬ Differentiation, 144
duced by, 9 TLI values and, 188
Chemohormonal adjuvant therapy, 318 Dihydrofolate reductase (DHFR), MTX binding
Chemotherapy to, 304
combination, 49 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyl-
features of, 280 tetrazolium bromide, 127
high-intensity Dose escalation, 379
with hematopoietic support, 378 Dose intensity, 279
without bone marrow support, 389 original concept of, 390
multiple cycles of, 56 Drug-induced amenorrhea (DIA), 331
neoadjuvant, 193 Dual-parameter flow cytometry, 177
without mastectomy, 264 Ductal carcinomas, in situ, 229
positron emission tomography scan in, 427 Duration, high-dose chemotherapy and, 56
SUBJECT INDEX 439
Early Breast Cancer Trialists’ Collaborative Gomp>ertzian model
Group (EBCTCG), 339 cell kill and, 378
Eastern Cooperative Oncology Group (ECOG), illustration of, 51
dose intensity and, 285 Granulocyte colony-stimulating &aor (G-CSF)
Emotional recovery, 374 dose-limiting toxicity and, 375
Emotional trauma, immediate reconstruction high-dose chemotherapy and, 383
prevents, 223 Taxol and, 398
Endocrine adjuvant therapy, 318 Granulocyte-macrophs^ colony-stimulating fee-
Endocrine approach, 314 tor (GM-CSF), high-dose chemotherapy
Endocrine Actors, adjuvant therapy and, 330 and, 383, 389
Enzyme, drug resistance and, 292 GROCTA trials, 318
Epidermal growth factor receptor Growth fectors, clinical implications of, 85
clinical significance of, 91 Growth rate of breast primary cultures, 2
high expression of, 57-58 Growth rate of tumors
Epidermal growth factor receptor expression, Gompertzian hypothesis and, 53
poor prognosis and, 34 metabolic heat pattern and, 155
Epirubicin, lonidamine and cyclophosphamide thermography prediction of, 153
and, 350 GSTx gene, 182
«r&-B2 gene, transformation of HBEC and, 11
Estrogpn receptor (ER) Hcii rodent mammary epithelial cells, 108
breast tumor proliferating cells and, 144 Hematopoietic support technology, 383
progesterone receptor inverse relation to, 188 Heparin-binding growth fector, pentosan poly-
prognostic information provided by, 272 sulfete and, 63
tamoxifen and, 334 HER2/neu/c-«»^-B2 gene-, 94
Estrogen receptor status, adjuvant tamoxifen Histolc^c type of invasive breast carcinoma, 114
and, 315 Hormonal manipulations, 418
Estrogen-regulated proteins, 88 Hormonal therapy, TLl values and, 189
External beam therapy, 264 Host antimonoclonal antibody (HAMA) re¬
sponse, 411
Huggins carcinogen-induced rat mammary car¬
Fatigue, 375
cinoma, 65
Ferritin, serum, elevation of, 159
Human breas^ epithelial cells (HBEC), 3
Fibroblast growth factor gene family, 22
cAMP-dependent protein kinase and, 102
Fibroblasts, rat embryo, 112
cytokine production and response and, 126
Fine-needle cytology, 194
overexpression of c-erb-B2 gene and, 36
Flow cytometry, cell cycle changes and, 175
Hypoftactionated protocol (IHF), 265
'*F-Fluoro-2-deoxy-D-glucose (FDG), 424
5-Fluorouracil (5-FU), drug resistance and,
Immortalization
306
mechanisms of, 5
Focal hot spots, thermography and, 154
wild-type p53 activity and, 112
Free radical-mediated drug cytotoxicity, 301
Immunocytochemistry
Frequent mutations in breast cancer, 21
c-€rb-B2 oncoprotein and, 167
marker expression studied by, 144
Cjamma interferon, 412 p53 protein expression evaluated by, 116
Gene expression, NM23-H1 loss of heterozy¬ Immunoscintigraphy, 429
gosity and, 138 Immunotherapy with polymorphic epithelial
Gene produrts, drug resistance and, 292 mucin-based immunogens, 40
Genotypic alterations, antigens showing, 34 Implants
Glucose metabolism, 423 complications with use of, 247
Glutathione peroxidase (GSHPx), drug resis¬ p)crmanent expandable, 247
tance and, 302 Inflatable devises, 252
Glutathione S-transferase (GST), drug resistance Insulin-like growth fector (IGF)-1, somatuline
and, 298 effect on, 364
Gluteus area, 232 Insulin-like growth fector-1-receptor, human
Glycosylation of polymorphic epithelial mucin, breast cancer and, 91
39 int-2lbcl-l gene, 95
Goldie-Coldman hypothesis, 50 int-2 gene, IL-6 stimulation and, 127
440 ANNALS NEW YORK ACADEMY OF SCIENCES
int-Z locus, activation of, 22 Patey modified radical, 219
Intcrleukin-6, 127 radical, immediate reconstruction with pros¬
Interleukin-8, 127 thesis following, 254
Intracytoplasmic lumina, 161 reconstruction after, 219
Intraductal permeation, 212 subcutaneous, immediate reconstruction fol¬
Intranuclear incorporation, 207 lowing, 247
Intratumor injection, 205 MCF-10 cells, immortalization of, 5
Inverse rule of dose and cell kill, 279 MCF-lOA ceUs, 102
5-[‘^®I]Iodo-2'-deoxyuridine, 127 cytokine production and response and, 126
tumor targeting protential of, 204 mdr genes, drug resistance and, 294
Iron metabolism, breast carcinoma and the role Megatrials, need for, 345
of, 159 Menopausal symptoms, 375
Isodose, 265 Metabolite, 206
Metastatic breast cancer (MBC), lonidamine
JC70 monoclonal antibody, 72 and, 349
Methotrexate (MTX), drug resistance and, 304
Kaplan-Meier method, 221 Microautoradiography, 206
Keratin-positive cells, 33 Milan CMF trials, 333
Ki-67 dose intensity and, 285
immunocytochemical determination of, 156 Trial I, 213
proliferating activity evaluated by, 167 Trial II, 215
Kinetic concepts, 48 Trial III, 216
Modulators, growth factor, 64
Latissimus dorsi musculocutaneous flap Monoclonal antibody (MAb)
delayed reconstruction and, 231 human breast cancer markers and, 144
impact of, 220 radiolabeled, 407
Lcucovorin (N*-formyl tetrahydrofolate), 305 Monoclonal antibody B72.3, TAG-72 and, 408
Liposomes, MAb-labeled, 429 Monoclonal antibody CC49, TAG-72 and, 407
Lobectomy, 212 Monoclonal antibody-labeled liposomes, 429
Local-regional administration, efficient incor¬ Monocyte colony-stimulating factor, 132
poration of lUdR by, 205 Mouse mammary tumor virus, 21
Local-regional failure, 268 MTSVl-7 ceU line, 36
S-phase influence on, 194 MUC-1 gene, 39
Local-regional treatment, 271 Multiple cycles of chemotherapy, 56
Log-kill model, 49
Multiple-cycle high-dose chemotherapy, 384
Lonidamine, 349
Multiple-modality therapy, premenopausal women
Loss of heterozygosity
and, 342
loci on chromosomes and, 121
Myelosuppression, 410
mutations in primary breast tumors and, 25
NM23-H1 cell a target of, 136
^Naples GUN-1 adjuvant trial, 334
Lung metastases, 160
National Surgical Adjuvant Breast Project
Luteinizing hormone-releasing hormone (LHRH)
(NSABP), 333
analogs, 333
Lymph node metastases, 425 Nausea and vomiting, 375
Lymph node status, pl85 and, 171 Needles, metal guide, 264
Neoadjuvant chemotherapy, S-phase prognostic
A/Iaintenance treatment, lonidamine as, 351 value and, 193
Mammary gland development, 2 Neovascularization, metastatic spread of breast
Marked mononuclear cell reaction, 131 cancer and, 64
Marker expression, cell differentiation and, 145 Neutropenia, 375
Mastectomy Nipple-areolar complex reconstruction, 237
Halsted, QUART technique and, 213 NM23-H1 cell, hypothetical suppressor func¬
Halsted radical, 220 tion of, 136
locally advanced breast cancer without, 264 NM23-H1 gene, LOH effect on, 25
Madden modified radical, 219 Nodal status, thermographic findings and, 155
modified radical (MRM), 229 Node metastatic diffusion, 151
immediate reconstruction following, 247 Node-negative tumors, 271
SUBJECT INDEX 441
Nodes, multiple involved, chemotamoxifen tamoxifen and, 334
treatment and, 325 Prognosis, S-phasc fraction and, 193
Nolvadex Adjuvant Trial Organization (NATO), Prognostic factors, 86
335 biological, 272
Nonsurgical approaches, S-phase fraction and, clinical use of, 274
197 neoadjuvant chemotherapy and brachytherapy
Notch gene &mily, 23 and, 268
Prognostic implications of angiogenesis, 75
Oncogene products, 167 Prognostic indicator, thermography as, 153
Oncogenes, cytokine production and response Prolactin receptor, tamoxifen and, 334
and, 126 Proliferating activity, c-erb-B2 oncoprotein and,
167
p53 gene Proliferating cell nuclear antigen (PCNA), 175
chromosome 17pl3.3 and, 120 Proline, glutamic acid, serine, threonine (PEST)
germline mutations of, 25 sequence, 23
mutations and overexpression of, 117 Prosthesis
prognostic p>otential of, 274 double-lumen, 247
progression vs. initiation and, 34 external, 223
transformation of HBEC and, 12 getting accustomed to, 258
wild-type, 108 radical mastectomy and immediate reconstruc¬
pl85 oncoprotein, 167-168 tion with, 254
Pain relief, 370 silicone, 236
Partial thromboplastin time, 66 submuscular implantation of, 220
Patient tissue expander versus, 229
breast reconstruction decision of, 233 Protooncogenes, increased expression of, 33
intelligent recommendations to, 315 pS2 protein, 88
participation of, 229 pTHH59, 139
quality of life of, 372 Ptosis, creation of, 252
Pentosan polysulfate, heparin-binding growth pYNZ22, 139
factor blockade with, 63
Percutaneous, ultrasound-guided injection, in- C^uadrantectomy, 212
tratumoral administration by, 205 Quality of life, 372
Permanent expandable implants (PEI) {see Im¬
QUART technique, 213
plants)
Pharmacokinetics, lUdR injection and, 209
R.adial breast resection, 212
Plasminogen activators, 89
Radioiodouracil, 207
Platelet-derived endothelial cell growth factor,
Radioisotope-charged MAb-labeled liposomes.
79
430
Ploidy, prognostic information provided by, 272
Radiolabeled monoclonal antibody (MAb), 407
Point mutation, p53 gene, 124
Randomized trials
Polychemotherapy
dose assessment and, 391
Gompertzian hypothesis and, 53
usefulness of, 316
tamoxifen and, 316
Polymerase chain reaction, 115 ms oncogene, transformation of HBEC and, 9
Polymorphic epithelial mucin, aberrant glyco- Bh gene, transformation of HBEC and, 12
sylation of, 39 Reconstruction
Polyspecific artificial carriers, 429 breast
Positron emission tomography (PET) of glucose advantages of immediate, 235
metabolism, 423 alternatives in, 246
Postmenopausal women, adjuvant chemother¬ complications of, 235
apy in, 315 delayed, 231
Productive fibrosis, 148 immediate, 229
Progesterone receptor impact of, 219
arrest of DNA synthesis and, 144 mastectomy and, 228
c-er&-B2 oncogene and, 183 with prosthesis, 254
epithelial expression of, 148 nipple-areolar complex, 237
estrogen receptor inverse relation to, 188 patients who refuse, 256
442 ANNALS NEW YORK ACADEMY OF SCIENCES
Recurrence reconstructive, impact of, 219
Icxal, reconstruction and, 225 Survival
mastectomy done for, 266 adjuvant systemic therapy and, 313
tamoxifen versus chemotherapy and, 320 adjuvant therapy improves, 331
Relapse, predictive value for site of, 96 di^ase-frce, 282
Repair mechanisms, altered, 291 neoadjuvant chemotherapy and brachytherapy
Resistance and, 268
alkylating ^nt, 303 ovarian suppression and, 344
antimetaboli^e, 304 quality of life and, 373
cyclophosphamide, 303 reconstruction and, 219
drug S-phase fraction influence and, 194
antineoplastic, 289 tamoxifen versus chemotherapy and, 320
high-dose chemotherapy and, 382 TLl values and, 188
mechanisms of, 291 Syngeneic model system, 40
random mutations and, 50
drug-metabolizing enzymes and, 297 T\G-72, MAb CC49 targets, 407
multidrug, 292 Tamoxifen, 57
P-glycoprotcin-mediated, 292 aTTom Study and, 346
topoisomerases and, 295 cell cycle kinetic effects of, 174
Response to treatment chemotherapy versus, 319
lonidamine and, 352 choice of, 315
low S-phase fraction patients and, 197-200 estrogen receptor-negative tumors and, 334
none versus partial and complete, 283 GSTt gene expression and response to, 182
Taxol and, 400 premenopausal women and, 341
second-line hormone therapy and, 357
S-phase fraction somatuline and, 362
mitotoxicity of chemotherapy and, 57 Tandem repeats domain, 39
prognostic value of, 193 Targeting
S-phase index, chromosome location and, 121 MAb-labeled liposomes in, 429
Scavenging enzymes catalase, drug resistance tumor, radioio^nated lUdR and, 207
and, 302 vascular, 80
Second-line hormone therapy, tamoxifen con¬ Targets, tumor-associated antigens as, 35
tinuation during, 357 TART, 215
Selective medical treatment, 191 Taxol
Sequential chemotherapy, 56 cardiotoxicity of, 403
Sexual concerns, 375 G-CSF and, 398
Single-strand conformation polymorphism analy¬ T47D cells, TNF-alpha and, 127
sis, 114 Therapeutic potentials, radiolabeled lUdRand,
Somatostatin receptors, 92 207
Somatuline, tamoxifen and, 362 Therapy, resistance to, 49
Split-course interstitial brachytherapy with a Thermography, breast, 153
source shift (SCISS), 265 ^H-Thymidine labeling index (TLl)
Statin, mechanism of tamoxifen and, 175 cell kinetics assessed by, 170
Stem cell hierarchy hypothesis, 143 cell kinetics evaluated as, 186
Steroid receptor, 87 prognostic relevance of, 273
c-crb-B2 oncoprotein and, 167 Tissue expander
prognostic information provided by, 272 Baker, 232
tamoxifen and, 334 prosthesis versus, 229
Stimulation of human breast cancer»» ww, 418 Radovan, 232, 246
Submuscular pocket Topoisomerases, 295
anatomical borders of, 255 Toxicity
filling ports and, 247 dose intensity and, 286
immediate breast reconstruction and, 229 hematopoietic support technologies and, 384
Surgery lonidamine plus epirubicin and cyclophospha¬
abdominal, women smokers with previous, mide, 354
237 pentoxan polysulfate, 67
conservative, 212 Transcription factor, 112
SUBJECT INDEX 443
Transferrin, iron-bound, 159 Tumor necrosis fiictor, 413
Transforming growth fector (TGF)-alpha, cul¬ Tumor/nontumor radioactivity incorporation
tures treated with, 127 ratios, 207
Transforming growth faaor-alpha gene, 103 Tumors, large primary, chemotamoxifen treat¬
Transforming growth factor-beta, tamoxifen ment for, 325
and, 316
Transforming growth factor-beta-1, angiogenic Ultrastructural study, iron metabolism, 159
response to, 78 Urinary excretion of radioactivity, 207
Transgenic mice, human MUC-1 gene and, 41 Urokinase, 132
Transverse rectus abdominis myocutaneous
(TRAM) flap
complications with use of, 247 Vascular targeting, 80
delayed reconstruction and, 231 Vector tubes, plastic, 264
impact of, 220 Vinblastine, doxorubicin, thiotepa, fluoxymes-
Tumor aggressiveness, NM23-H1 loss of hetero¬ terone (VATH), 51
zygosity and, 139
Tumor-associated antigens (TAA), 31, 407 Wud -type p53 gene, 108
Tumor/blood ratio, 207 World CXerview of Adjuvant Systemic Therapy
Tumor heterogeneity, outcome influenced by, for Early Breast Cancer, 313
280 World-Wide Overview, 51

Index of Contributors
Addamo, G. F., 389-397 Bonacci, R., 148-152
Adclstein, S. J., 204-211 Bonichon, F., 182-185
Aldrighetti, D., 318-329 Bontenbal, M., 85-101
Alvarado, M. E., 1-20 Bravo, A. 1., 143-147
Amadori, D., 186-192, 418-422 Brema, F., 418-422
Amaducci, L., 186-192 BurcheU, J., 31-47
Amalric, R., 259-263 Buttitta, F., 114-119
Amoroso, D., 318-329
Arbuck, S., 398-402
Ardizzoni, A., 389-397 Calaf, G., 1-20
Augustine, S., 406—417 Caligo, M. A., 136-142
Ayme, Y., 259-263 Callahan, R., 21-30,108-113,114-119,
120-125
Calvo, S., 126-130
Badellino, F., 219-226 Camoriano, A., 349-356
BaiUet, F., 264-270 Campani, D., 114-119, 148-152, 167-
Baldassarre, G., 102-107 173
Baldini, E., 349-356, 418-422 Canavese, G., 219-226
Baldini, F., 403-405 Canetta, R., 398-402
Ballare, C., 143-147 Cannata, D., 362-366
Baranowska-Kortylcwicz, J., 204-211 Canobbio, L., 362-366
Barone, C., 349-356 Cappa, A. P. M., 120-125
Basolo, F., 126-130 Cappellini, M., 318-329
Baum, M., 313-317 Carlomagno, C., 330-338
Beghc, F., 367-371 Castagnetta, L., 318-329
BeUettieri, R. J., 372-377 Catturich, A., 219-226
Berdichevsky, F., 31-47 Cecchetti, D., 114-119, 167-173
Berkery, R., 398-402 Chauveinc, L., 264-270
Bemardi, A., 120-125 Ciardiello, F., 102-107
Bems, P. M. J. J., 85-101 Clarke, M., 339-348
Berrino, P., 246-253 Coindre, J. M., 182-185
BerteUi, G., 357-361 Colcher, D., 406-417
Beuvon, F., 131-135 CoUecchi, P., 204-211
Beviglia, E., 254-258 CoUetta, A., 313-317
Bevilacqua, G., 136-142, 204-211 Collins, R., 339-348
Biadi, O., 403-405 Conaldi, P. G., 126-130
Bianco, A. R., 102-107, 330-338 Conte, P. F., 349-356, 403-405, 418-
Bianco, C., 102-107 422
BickneU, R., 71-84 Contu, A., 349-356
Bistocchi, M., 114-119 Cossu, F., 429-435
Boccardo, F., 318-329, 362-366 Costa, A., 212-218
445
446 ANNALS NEW YORK ACADEMY OF SCIENCES
Cowan, K. H., 182-185, 289-312 Gallahan, D., 21-30
Cropp, C., 21-30 Gallo, C., 330-338
Crown, J. P. A., 378-388, 398-402 Gallo, L., 318-329
Currie, V., 398-402 GaUotti, P., 418-422
Garau, A., 227-245
Gardin, G., 349-356, 418-422
Dalrymple, G., 406-417 Garrone, O., 389-397
Danova, M., 174-181 GentiUni, P., 418-422
DeLap, R., 63-70 Gherarducci, G., 403-405
De Laurentiis, M., 330-338 Ghimenti, C., 136-142
Del Mastro, L., 330-338, 389-397 Giani, C., 148-152
de Luca, F., 167-173 Giannessi, P. G., 349-356, 403-405,
Demontis, B., 227-245 418-422
de Negri, F., 148-152 Gibelli, N., 174-181
De Pladdo, S., 330-338 GigUotti, A., 148-152
d’Errico, F., 254—258 Gilewski, T. A., 378-388, 398-402
De Sanctis, C., 318-329 Giordano, M., 174-181
DeVita, V. J., Jr., 279-288 Giuliani, L., 204-211
Diella, F., 21-30, 114-119, 120-125 Gray, R., 339-348
Di Luca, L., 204-211 Gualde, N., 182-185
Di Martino, L., 227-245
Di Sacco, S., 204-211
Dorion-Bonnet, F., 182-185 Hakes, T. B., 398-402
D’Souza, B., 31-47 Hamilton, N., 378-388
Durand, J. C., 193-203 Harris, A. L., 71-84
Durand, M., 182-185 Harrison, K., 406-417
Head, J. F., 153-158, 159-166
Heelan, R., 398-402
Euiott, M. C., 159-166 Holdeman, K., 406-417
Elliott, R. L., 153-158, 159-166 Horak, E. R., 71-84
Estienne, M., 219-226 Hortobagyi, G. N., 423-428
Estrada, S., 1-20 Housset, M., 264-270
Hudis, C. A., 378-388, 398-402
Hynes, N. E. 108-113
Fabbri, R., 148-152
Falcone, V., 126-130
Farris, A., 318-329 lacobelli, S., 318-329
FenneUy, D., 378-388 lanniello, G., 349-356
Ferrario, E., 254-258
Fierabracci, P., 148-152
Fiore, L., 126-130 Joshi, S., 406-417
Fisherman, J., 398-402
Foekens, J. A., 85-101
Fontanini, G., 167-173 Kassis, A. L, 204-211
Fourquet, A., 193-203 Kim, E. E., 423-428
Franchelli, S., 246-253 KUjn, J. G. M., 85-101
Francis, P., 378-388 Kritz, A., 378-388